Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Younger age at onset of colorectal cancer is associated with increased patient's delay

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Late onset of subacute cutaneous lupus erythematosus following pembrolizumab therapy

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  1. Effectiveness and safety of switching from originator to biosimilar adalimumab in patients with psoriasis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Independent evolution of cutaneous lymphoma subclones in different microenvironments of the skin

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Branched evolution and genomic intratumor heterogeneity in the pathogenesis of cutaneous T-cell lymphoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Overall Survival in Mycosis Fungoides: A Systematic Review and Meta-Analysis

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  • Franz Trautinger
  • Johanna Eder
  • Chalid Assaf
  • Martine Bagot
  • Antonio Cozzio
  • Reinhard Dummer
  • Robert Gniadecki
  • Claus-Detlev Klemke
  • Pablo L Ortiz-Romero
  • Evangelia Papadavid
  • Nicola Pimpinelli
  • Pietro Quaglino
  • Annamari Ranki
  • Julia Scarisbrick
  • Rudolf Stadler
  • Liisa Väkevä
  • Maarten H Vermeer
  • Sean Whittaker
  • Rein Willemze
  • Robert Knobler
Vis graf over relationer

In order to provide a common standard for the treatment of mycosis fungoides (MF) and Sézary syndrome (SS), the European Organisation for Research and Treatment of Cancer-Cutaneous Lymphoma Task Force (EORTC-CLTF) published in 2006 its consensus recommendations for the stage-adapted selection of management options for these neoplasms. Since then, the understanding of the pathophysiology and epidemiology of MF/SS has advanced, the staging system has been revised, new outcome data have been published and novel treatment options have been introduced. The purpose of the present document is to update the original recommendations bearing in mind that there are still only a limited number of controlled studies to support treatment decisions for MF/SS and that often treatment is determined by institutional experience and availability. This consensus on treatment recommendations was established among the authors through a series of consecutive consultations in writing and a round of discussion. Recommended treatment options are presented according to disease stage, whenever possible categorised into first- and second-line options and supported with levels of evidence as devised by the Oxford Centre for Evidence-Based Medicine (OCEBM). Skin-directed therapies are still the most appropriate option for early-stage MF, and most patients can look forward to a normal life expectancy. For patients with advanced disease, prognosis is still grim, and only for a highly selected subset of patients, prolonged survival can be achieved with allogeneic stem cell transplantation (alloSCT). There is a high need for the development and investigation in controlled clinical trials of treatment options that are based on our increasing understanding of the molecular pathology of MF/SS.

OriginalsprogEngelsk
TidsskriftEuropean journal of cancer (Oxford, England : 1990)
Vol/bind77
Sider (fra-til)57-74
Antal sider18
ISSN0959-8049
DOI
StatusUdgivet - maj 2017

ID: 52396995